Smart Nanoparticles Bust Tumor Fibrosis and Unlock Immune Attack on Cancer
Fucoidan-based nanoparticles targeting senescent cells dissolve fibrotic barriers in tumors, restoring immune infiltration and boosting immunotherapy response.
Summary
Scarred (fibrotic) tissue is packed with aging-like cells that block the immune system, and tumors that grow inside scarred organs often resist immunotherapy. Researchers found that a surface protein called P-selectin marks a subset of these senescent-like cells. They built nanoparticles from fucoidan, a sugar that sticks to P-selectin, and loaded them with either a senescent-cell-killing drug (navitoclax) or a drug that quiets senescent-cell signaling (dBET6). In mice, the particles reversed established liver and lung fibrosis, avoided the blood toxicity of the free drugs, and mainly destroyed one immunosuppressive macrophage type. In fibrotic liver and lung cancer models, this cleared the way for T cells and made tumors respond to checkpoint-based therapy. All the work was preclinical.
Detailed Summary
Fibrosis, the progressive scarring of organs such as the liver and lung, causes organ failure and also shields tumors from the immune system. Cells with senescent features are known drivers of this process, but they are heterogeneous. Existing senolytic drugs such as navitoclax and BET inhibitors also cause dose-limiting toxicities, including low neutrophil and platelet counts. The authors asked whether a specific subset of pathogenic senescent-like cells could be targeted precisely.
They first analyzed 58 human liver and lung fibrosis specimens plus healthy controls. P-selectin was significantly elevated in fibrotic tissue, and a subset of P-selectin-positive cells showed senescence features: p21 expression, absent Ki67, and reduced LaminB1. The same pattern appeared in CCl4-induced liver fibrosis and bleomycin-induced lung fibrosis in mice, where some P-selectin-positive cells were also SA-β-gal positive.
Using fucoidan-based nanoparticles that bind P-selectin, the team built senescence-modulating nanoparticles (SMNPs). FiNav carries the senolytic navitoclax, and FidBET6 carries the BRD4-degrading senomorphic dBET6. Dextran-based control particles do not bind P-selectin. After intravenous dosing in fibrotic mice, SMNPs accumulated preferentially in the diseased organ and inside P-selectin-positive, SA-β-gal-positive cells. Controls showed no organ-specific accumulation.
In treatment studies on established fibrosis, both SMNPs reduced collagen deposition and α-SMA-positive fibroblasts, at least as much as matched free drug. Control particles and free fucoidan did nothing. SMNPs also improved portal vein flow, with FiNav outperforming free navitoclax, and lowered ALT and AST. The particles eliminated neutropenia and thrombocytopenia, shortened bleeding times, and prevented the free-drug weight loss, leukopenia, lymphopenia and treatment-associated mortality.
Single-cell sequencing and ex vivo assays identified a P-selectin-positive, SA-β-gal-positive macrophage population as the main functional target. These cells show a senescence program (Cdkn1a, Cdkn2a, SASP genes) and lipid-associated macrophage features (Cd36, Mrc1, Spp1, Cd274). Their depletion within 36 hours preceded fibrosis resolution. Selectivity depended on P-selectin binding, lysosomal routing in macrophages, and a senescence-matched payload; paclitaxel-loaded particles lacked this selectivity and showed reduced antifibrotic activity. A comparable macrophage state was expanded in public human cirrhosis and lung fibrosis datasets (44 healthy and 5 cirrhotic liver, 51 healthy and 66 fibrotic lung samples).
SMNPs shifted the remaining macrophages toward antigen-presenting states, expanded T and B cells and mature dendritic cells, and raised IL-2, IL-4, IL-7 and IFN-γ. In mouse hepatocellular carcinoma and lung cancer models grown in fibrotic organs, tumors resisted first-line anti-PD-L1 combinations (with anti-VEGF or cisplatin). Adding FiNav to the regimen produced durable regression and better survival. FidBET6 showed similar synergy in the liver model. Caveats: all evidence is preclinical in mice, tumor P-selectin was silenced, and human data were transcriptional only.
Key Findings
- P-selectin was significantly elevated in 58 human liver and lung fibrosis specimens versus non-fibrotic controls, and a subset of P-selectin-positive cells carried senescence markers (p21 high, Ki67 absent, LaminB1 low).
- Fucoidan-based SMNPs accumulated selectively in the fibrotic liver or lung and in P-selectin+/SA-β-gal+ cells, while non-binding dextran control nanoparticles showed no organ-specific accumulation.
- FiNav (navitoclax) and FidBET6 (dBET6) both reduced collagen deposition and α-SMA+ fibroblasts in established liver and lung fibrosis, at least matching free drug; control particles and free fucoidan had no effect.
- SMNPs eliminated free-drug neutropenia and thrombocytopenia, shortened bleeding times, and prevented weight loss, leukopenia, lymphopenia and treatment-associated mortality.
- A P-selectin+/SA-β-gal+ lipid-associated-like macrophage was the principal target; FiNav depleted it within 36 hours, before fibrosis resolved, and a matching macrophage state was expanded in human cirrhosis and lung fibrosis datasets.
- SMNPs raised CD4+, CD8+ and B cells, mature dendritic cells, and IL-2, IL-4, IL-7 and IFN-γ, while lowering amphiregulin, CCL5 and IL-1β.
- In fibrotic HCC and NSCLC mouse models resistant to anti-PD-L1 regimens, FiNav plus therapy gave durable tumor regression and improved overall survival; FidBET6 showed similar synergy in liver cancer.
Methodology
The study combined human tissue analysis (58 fibrotic liver and lung specimens plus healthy controls, using IHC and multiplexed immunofluorescence) with mouse models of CCl4-induced liver fibrosis and bleomycin-induced lung fibrosis. Mice were treated with SMNPs, dextran control particles, matched free drugs or free fucoidan, and assessed for collagen, α-SMA, portal flow, serum enzymes, hematology, bleeding time and mortality. Target cells were identified by FACS-sorted P-selectin/SPiDER populations with scRNA-seq (MAST differential expression), ex vivo viability and BRD4 assays, and validation against public human scRNA-seq datasets. Syngeneic orthotopic HCC and lung KP tumors (P-selectin silenced) were grown in fibrotic organs and treated with SMNPs plus anti-PD-L1 combined with anti-VEGF or cisplatin, with randomization by baseline imaging. Exact group sizes and p-values were not available in the supplied text.
Study Limitations
All therapeutic data come from mouse models, and the human evidence is limited to tissue staining and public transcriptomic datasets. The authors note that senescence and lipid-associated macrophage programs are not exclusive to the targeted P-selectin-positive population, and the tumor models had P-selectin silenced to avoid confounding. Conflict-of-interest disclosures were not included in the supplied text, and the full text was truncated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
